{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:49:49Z","timestamp":1740142189585,"version":"3.37.3"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2214050003621"],"award-info":[{"award-number":["2214050003621"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004024","name":"Jinan University Scientific Research Cultivation and Innovation Fund","doi-asserted-by":"publisher","award":["11619356"],"award-info":[{"award-number":["11619356"]}],"id":[{"id":"10.13039\/501100004024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Flagship specialty construction project-General Surgery","award":["711003"],"award-info":[{"award-number":["711003"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>A 43-year-old female patient was found to have an abnormal liver function,\nabnormally elevated alpha-fetoprotein and space-occupying lesions in the liver on routine\nscreening. The patient came to our hospital for further diagnosis and treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case presentation:<\/jats:title>\n<jats:p>Investigations: Laboratory investigations, digital subtraction angiography (DSA)\nof the hepatic artery, abdominal ultrasound examination, and magnetic resonance imaging (MRI)\nscan were conducted using pathological staining and immunohistochemistry. Diagnosis: Clinical\ndiagnosis: cT3NxM0. Barcelona clinic liver cancer (BCLC) staging: BCLC stage C. China liver\ncancer (CNLC) staging: CNLC IIIa.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion:<\/jats:title>\n<jats:p>The patient was hospitalized for the first time for transcatheter arterial chemoembolization\n(TACE) and FOLFOX-based hepatic arterial infusion chemotherapy (HAIC). Then, the second\nand third hospital admissions were given HAIC based on FOLFOX. Camrelizumab and oncolytic\nvirus were also injected into the liver cancer through the microcatheter in the first three treatments.\nOn the fourth admission, the patient\u2019s indicators were improved, and the tumor shrank. Furthermore,\nas the patient suffered adverse reactions the first few times, we suspended the treatment\nof FOLFOX and the oncolytic virus. Before surgical treatment, lenvatinib was used throughout the\ntreatment. On the fifth admission, the patient underwent liver cancer resection.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>It proves the value of multiple combination therapy, which can provide guidance for patients with advanced hepatocellular carcinoma that cannot be surgically removed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009623666230801093031","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T05:12:09Z","timestamp":1691039529000},"page":"368-374","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report and Literature Review of Multi-drugs Synergy and Targeted\nComprehensive Treatment in Advanced Hepatocellular Carcinoma"],"prefix":"10.2174","volume":"24","author":[{"given":"Guanhua","family":"Lu","sequence":"first","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Avenue West, Guangzhou, 510630, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limin","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Avenue West, Guangzhou, 510630, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingrong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Avenue West, Guangzhou, 510630, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Avenue West, Guangzhou, 510630, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.jhep.2015.02.007","volume":"62","author":"Bruix J","year":"2015","unstructured":"Bruix J; Han KH; Gores G; Llovet JM; Mazzaferro V; Liver cancer: Approaching a personalized care. J Hepatol  2015,62(1),S144-1456","journal-title":"J Hepatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"Bruix J","year":"2011","unstructured":"Bruix J; Sherman M; Management of hepatocellular carcinoma: An update. Hepatology  2011,53(3),1020-1022","journal-title":"Hepatology"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000488035","volume":"7","author":"Zhou J","year":"2018","unstructured":"Zhou J; Sun HC; Wang Z; Cong WM; Wang JH; Zeng MS; Guidelines for diagnosis and treatment of primary liver cancer in China. Liver Cancer  2018,7(3),235-260","journal-title":"Liver Cancer"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"Zhou J","year":"2020","unstructured":"Zhou J; Sun H; Wang Z; Cong W; Wang J; Zeng M; Guidelines for the diagnosis and treatment of hepatocellular carcinoma. Liver Cancer  2020,9(6),682-720","journal-title":"Liver Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.biopha.2016.10.078","volume":"84","author":"Chacko S","year":"2016","unstructured":"Chacko S; Samanta S.; Hepatocellular carcinoma: A life-threatening disease. Biomed Pharmacother  2016,84,1679-1688","journal-title":"Biomed Pharmacother"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"Villanueva A.","year":"2019","unstructured":"Villanueva A.; Hepatocellular carcinoma. N Engl J Med  2019,380(15),1450-1462","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","volume":"72","author":"Faivre S","year":"2020","unstructured":"Faivre S; Rimassa L; Finn RS; Molecular therapies for HCC: Looking outside the box J Hepatol  2020,72(2),342-352","journal-title":"J Hepatol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","year":"2018","unstructured":"Management of hepatocellular carcinoma. J Hepatol EASL Clinical Practice Guidelines 2018,69(1),182-236","journal-title":"J Hepatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","volume":"146","author":"Yau T","year":"2014","unstructured":"Yau T; Tang VY; Yao TJ; Fan ST; Lo CM; Poon RT; Development of hong kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology  2014,146(7),1691-1700","journal-title":"Gastroenterology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"Park JW","year":"2015","unstructured":"Park JW; Chen M; Colombo M; Roberts LR; Schwartz M; Chen PJ; Global patterns of hepatocellular carcinoma management from diagnosis to death: The bridge study. Liver Int  2015,35(9),2155-2166","journal-title":"Liver Int"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/ijc.22655","volume":"121","author":"Jiang H","year":"2007","unstructured":"Jiang H; Meng Q; Tan H; Pan S; Sun B; Xu R; Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer  2007,121(2),416-424","journal-title":"Int J Cancer"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"Kudo M.","year":"2020","unstructured":"Kudo M.; Ueshima K.; Ikeda M.; Torimura T.; Tanabe N.; Aikata H.; Izumi N.; Yamasaki T.; Nojiri S.; Hino K.; Tsumura H.; Kuzuya T.; Isoda N.; Yasui K.; Aino H.; Ido A.; Kawabe N.; Nakao K.; Wada Y.; Yokosuka O.; Yoshimura K.; Okusaka T.; Furuse J.; Kokudo N.; Okita K.; Johnson P.J.; Arai Y.; Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut  2020,69(8),1492-1501","journal-title":"Gut"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"He M","year":"2019","unstructured":"He M; Li Q; Zou R; Shen J; Fang W; Tan G; Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs. sorafenib alone for hepatocellular carcinoma with portal vein invasion. JAMA Oncol  2019,5(7),953","journal-title":"JAMA Oncol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"Lyu N","year":"2018","unstructured":"Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol  2018,69(1),60-69","journal-title":"J Hepatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000343875","volume":"3","author":"Kudo M.","year":"2014","unstructured":"Kudo M.; Matsui O.; Izumi N.; Iijima H.; Kadoya M.; Imai Y.; Okusaka T.; Miyayama S.; Tsuchiya K.; Ueshima K.; Hiraoka A.; Ikeda M.; Ogasawara S.; Yamashita T.; Minami T.; Yamakado K.; JSH Consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the liver cancer study group of Japan. Liver Cancer  2014,3(3-4),458-468","journal-title":"Liver Cancer"},{"key":"ref=16","first-page":"O2100608","volume":"2021","author":"Li Q.J.","year":"2021","unstructured":"Li Q.J.; He M.K.; Chen H.W.; Fang W.Q.; Zhou Y.M.; Xu L.; Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase III Trial. J Clin Oncol  2021,2021,O2100608","journal-title":"J Clin Oncol"},{"key":"ref=17","first-page":"395","volume":"67","author":"Lyu N","year":"2018","unstructured":"Lyu N; Lin Y; Kong Y; Zhang Z; Liu L; Zheng L; FOXAI: A phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular  carcinoma GUTLetter; Comment  2018,67(2),395-396","journal-title":"GUTLetter; Comment"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"Kudo M","year":"2018","unstructured":"Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet  2018,391(10126),1163-1173","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"Qin S.","year":"2020","unstructured":"Qin S.; Ren Z.; Meng Z.; Chen Z.; Chai X.; Xiong J.; Bai Y.; Yang L.; Zhu H.; Fang W.; Lin X.; Chen X.; Li E.; Wang L.; Chen C.; Zou J.; Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol  2020,21(4),571-580","journal-title":"Lancet Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.21037\/apm-20-2572","volume":"10","author":"Wang K.","year":"2021","unstructured":"Wang K.; Wang H.; Lv Y.; Liu H.; Liu J.; Zhang Y.; Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: A case report. Ann Palliat Med  2021,10(1),803-809","journal-title":"Ann Palliat Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.2147\/CMAR.S304820","volume":"13","author":"Wei F","year":"2021","unstructured":"Wei F; Huang Q; He J; Luo L; Zeng Y.; Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: A short-term prognostic study. Cancer Manag Res  2021,13,4233-4240","journal-title":"Cancer Manag Res"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"Russell SJ","year":"2012","unstructured":"Russell SJ; Peng KW; Bell JC; Oncolytic virotherapy. Nat Biotechnol  2012,30(7),658-670","journal-title":"Nat Biotechnol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"Kaufman HL","year":"2015","unstructured":"Kaufman HL; Kohlhapp FJ; Zloza A; Oncolytic viruses: A new class of immunotherapy drugs. NAt Rev Drug Discov  2015,14(9),642-662","journal-title":"NAt Rev Drug Discov"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"Bommareddy PK","year":"2018","unstructured":"Bommareddy PK; Shettigar M; Kaufman HL; Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol  2018,18(8),498-513","journal-title":"Nat Rev Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"Lawler SE","year":"2017","unstructured":"Lawler SE; Speranza MC; Cho CF; Chiocca EA; Oncolytic viruses in cancer treatment: A review. JAMA ONCOL  2017,3(6),841-849","journal-title":"JAMA ONCOL"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/gut.2009.196519","volume":"59","author":"Boozari B","year":"2010","unstructured":"Boozari B; Mundt B; Woller N; Struver N; Gurlevik E; Schache P; Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. GUT  2010,59(10),1416-1426","journal-title":"GUT"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"Heo J","year":"2013","unstructured":"Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat Med  2013,19(3),329-336","journal-title":"Nat Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"eaam7996","DOI":"10.1126\/scitranslmed.aam7996","volume":"9","author":"Zhang H","year":"2017","unstructured":"Zhang H; Li K; Lin Y; Xing F; Xiao X; Cai J; Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci Transl Med  2017,9(404),eaam7996","journal-title":"Sci Transl Med"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40880-017-0227-2","volume":"36","author":"He CB","year":"2017","unstructured":"He CB; Lao XM; Lin XJ; Transarterial chemoembolization combined with recombinant human adenovirus type 5 h101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: A prognostic nomogram study Chin J Cancer  2017,36(1),59","journal-title":"Chin J Cancer"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1186\/s12885-015-1715-x","volume":"15","author":"Lin XJ","year":"2015","unstructured":"Lin XJ; Li QJ; Lao XM; Yang H; Li SP; Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC CANCER  2015,15,707","journal-title":"BMC CANCER"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009623666230801093031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/219320\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568009623666230801093031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T09:25:54Z","timestamp":1711704354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/219320\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009623666230801093031","relation":{},"ISSN":["1568-0096"],"issn-type":[{"type":"print","value":"1568-0096"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}